New treatments for Alzheimer's Disease using protein activators
Official title: Direct protein phosphatase 2A (PP2A) activators as novel Alzheimer’s Disease (AD) therapeutics
Funded at Atux Iskay Group LLC · NIH-11041145 · Data updated 2026-11-12
This study is looking at new pills that could help fight Alzheimer's Disease by boosting a protein that may help reduce brain inflammation and other issues related to the condition, and it's testing how well these pills work in different models.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Atux Iskay Group LLC NIH-funded |
| Lab location | 1 site (Plainsboro, United States) |
| Project start | September 15, 2020 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $828,594 |
| NIH project number | 5R44AG071040-03 |
| Project ID | NIH-11041145 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's Disease or related dementias.
✕Less likely to help
Patients under the age of 65 or those without symptoms of Alzheimer's Disease may not benefit from this research.
What this research studies
This research focuses on developing new compounds that activate protein phosphatase 2A (PP2A) to combat Alzheimer's Disease (AD). By increasing the activity of PP2A, the research aims to address the underlying causes of AD, such as tau phosphorylation and neuroinflammation. The compounds are designed to be taken orally and are expected to reach the central nervous system effectively. The study involves testing these compounds in various models to evaluate their effectiveness in slowing down or preventing the progression of AD.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly slow the progression of Alzheimer's Disease, improving quality of life for patients.
How similar studies have gone: While the approach of targeting PP2A is relatively novel, similar strategies in other neurodegenerative conditions have shown promise, indicating potential for success.
Where this research is happening
-
Atux Iskay Group LLC
Plainsboro, United States Active
Researchers
- Principal investigator: Ohlmeyer, Michael — Atux Iskay Group LLC
- Study coordinator: Ohlmeyer, Michael
Related research
Other NIH-funded projects on the same topics.
-
Alzheimer’s disease and related brain changes linked to chemicals in the body
This NIH grant supports a patient-centered effort to map how environmental exposures and body chemistry relate to Alzheimer’s disease and related dementias.
-
Understanding how everyday exposures affect Alzheimer's disease progression
A national research effort is studying how environmental exposures, gut health, diet, and metabolism relate to Alzheimer's and related dementias to identify new ways to diagnose and treat these conditions.
-
How environment, gut health, and metabolism affect Alzheimer’s disease
This grant looks at how environmental exposures, gut microbes, diet, and metabolism influence Alzheimer’s disease and related dementias.
-
Understanding how chemical exposures affect Alzheimer's disease progression
This project studies how environmental chemicals and other biological factors influence brain health and the course of Alzheimer’s disease and related dementias.
-
Understanding how brain hyperexcitability and sex differences affect Alzheimer’s disease
This grant tests whether brain hyperexcitability linked to a genetic risk (APOE4) and sex differences contribute to memory decline in Alzheimer’s disease, using computer simulations and mouse data to guide potential human treatments.
-
CNS Exosomes and Adaptive Immunity in Alzheimer’s Disease
This project studies how tiny brain vesicles called exosomes may activate the body's immune system in Alzheimer’s disease, with the goal of understanding mechanisms that could lead to new treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.